The microbiome as a pharmacologic variable: Defining when microbial drug metabolism becomes clinically actionable
Abstract
Interindividual variability in drug exposure, toxicity, and response is usually evaluated through host-centered covariates, including organ function, pharmacogenomic variation, route, formulation, co-medications, adherence, and enzyme- or transporter-mediated drug interactions. In selected settings, microbial metabolism may represent an additional source of pharmacologic variability, but only when microbial activity changes a drug-specific outcome at a magnitude that can alter development or care. A clinical pharmacology framework for microbial drug metabolism should begin with absorption, distribution, metabolism, and excretion (ADME), pharmacodynamic response, route of administration, and microbial compartment exposure. The relevant questions are whether a drug or drug-related product reaches a microbial compartment, whether microbial activity transforms the compound or modifies the host interface, whether that activity varies across patients or contexts, and whether the effect changes exposure, response, toxicity, monitoring, formulation, prescribing, labeling, or risk management. Digoxin, levodopa, irinotecan, sulfasalazine, and metformin illustrate distinct routes from microbial plausibility to pharmacologic consequence. Microbial relevance should be judged against accepted pharmacologic denominators rather than microbiome change alone. The microbiome should not become a routine clinical variable for every drug. It becomes relevant when microbial biology changes what a…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.